Interpretation of similarities and differences in Kawasaki disease guidelines at home and abroad.
10.7499/j.issn.1008-8830.2406041
- Author:
Yan PAN
1
;
Li-Jian XIE
;
Fu-Yong JIAO
Author Information
1. Children's Hospital of Shaanxi Provincial People's Hospital/Diagnosis and Treatment Center of Kawasaki Disease of Shaanxi Province Xi'an 710068 China.
- Publication Type:Review
- Keywords:
Child;
Diagnosis;
Guideline;
Interpretation;
Kawasaki disease;
Treatment
- MeSH:
Mucocutaneous Lymph Node Syndrome/drug therapy*;
Humans;
Practice Guidelines as Topic
- From:
Chinese Journal of Contemporary Pediatrics
2025;27(2):144-147
- CountryChina
- Language:Chinese
-
Abstract:
This paper comprehensively compares the Kawasaki disease (KD) guidelines from seven countries/regions, including China, Argentina, Europe, Italy, Japan, Spain, and the United States, as retrieved from the PubMed database. It analyzes the similarities and differences in KD diagnosis and treatment among these guidelines. The results show that all guidelines consistently recommend a single infusion of immunoglobulin at a dosage of 2 g/kg as the first-line treatment for KD, and none advocate for the routine use of methylprednisolone or prednisone as standalone first-line treatment options for KD. However, there are some differences among the guidelines regarding classification, diagnostic criteria, and specific treatment methods for KD. Therefore, it is essential to further strengthen international collaboration in guideline development and conduct multicenter clinical research in the future, aiming to achieve a higher level of expert consensus, thereby promoting the enhancement of KD diagnosis and treatment.
